Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Bortezomib and Pegylated Liposomal Doxorubicin as Induction Therapy for Adult Patients with Symptomatic Multiple Myeloma: Cancer and Leukemia Group B Study 10301.

Robert Z. Orlowski, MD, PhD, Bercedis L. Peterson, PhD, Ben Sanford, Asher A. Chanan-Khan, MD, Lee M. Zehngebot, MD, Peter R. Watson, MD, Michael A. Caligiuri, MD, Richard A. Larson, MD, the Cancer Leukemia Group B

Blood (2006) 108 (11): 797.

https://doi.org/10.1182/blood.V108.11.797.797

Published: 2006

Journal Articles

Analysis of Survival, AML Transformation, and Transfusion Independence in Patients with High-Risk Myelodysplastic Syndromes (MDS) Receiving Azacitidine Determined Using a Prognostic Model.

Lewis R. Silverman, MD, David R. McKenzie, MS, Bercedis L. Peterson, PhD, Erin P. Demakos, RN, CCRC, James F. Holland, MD, Richard R. Larson, MD, The Cancer Leukemia Group B (CALGB).

Blood (2005) 106 (11): 2523.

https://doi.org/10.1182/blood.V106.11.2523.2523

Published: 2005

Journal Articles

Azacitidine Prolongs Survival and Time to AML Transformation in High-Risk Myelodysplastic Syndrome (MDS) Patients ≥ 65 Years of Age.

Lewis R. Silverman, MD, David R. McKenzie, MS, Bercedis L. Peterson, PhD, Erin P. Demakos, RN, CCRC, Neil T. Malone, MA, James F. Holland, MD, Richard A. Larson, MD, The Cancer Leukemia Group B (CALGB).

Blood (2005) 106 (11): 2524.

https://doi.org/10.1182/blood.V106.11.2524.2524

Published: 2005

Journal Articles

Rates of Infection and Bleeding Are Not Increased in Patients with Myelodysplastic Syndromes (MDS) Treated with Azacitidine Compared with Supportive Care.

Lewis R. Silverman, MD, David R. McKenzie, MS, Bercedis L. Peterson, PhD, Rosalie Odchimar-Reissig, RN, MSN, CCRC, Randy Hinkle, RPh, Jay T. Backstrom, MD, Richard A. Larson, MD, The Cancer Leukemia Group B (CALGB).

Blood (2005) 106 (11): 2525.

https://doi.org/10.1182/blood.V106.11.2525.2525

Published: 2005

Journal Articles

Response Rates Using International Working Group (IWG) Criteria in Patients with Myelodysplastic Syndromes (MDS) Treated with Azacitidine.

Lewis R. Silverman, MD, David R. McKenzie, MS, Bercedis L. Peterson, PhD, Carlos M. De Castro, MD, John Ellerton, MD, Kathryn N. Knapp, MS, C.L. Beach, PharmD, Richard A. Larson, MD, The Cancer Leukemia Group B (CALGB).

Blood (2005) 106 (11): 2526.

https://doi.org/10.1182/blood.V106.11.2526.2526

Published: 2005

Journal Articles

A New Validated Myelodysplastic Syndrome (MDS) Prognostic Model for Use When Cytogenetics Are Unavailable.

Lewis R. Silverman, MD, Ulrich Germing, MD, PhD, David R. McKenzie, MS, Bercedis L. Peterson, PhD, Richard A. Larson, MD, The Cancer Leukemia Group B (CALGB).

Blood (2005) 106 (11): 2527.

https://doi.org/10.1182/blood.V106.11.2527.2527

Published: 2005

Journal Articles

Response Rates in Patients with Acute Myeloid Leukemia (AML), Treated with Azacitidine, Using WHO and International Working Group (IWG) Criteria for Myelodysplastic Syndrome (MDS).

Lewis R. Silverman, MD, David R. McKenzie, MS, Bercedis L. Peterson, PhD, Richard M. Stone, MD, Bayard L. Powell, MD, Christy Mayo, MS, Jay T. Backstrom, MD, MPH, Richard A. Larson, MD, The Cancer Leukemia Group B (CALGB)

Blood (2005) 106 (11): 1848.

https://doi.org/10.1182/blood.V106.11.1848.1848

Published: 2005

NARROW

Bortezomib and Pegylated Liposomal Doxorubicin as Induction Therapy for Adult Patients with Symptomatic Multiple Myeloma: Cancer and Leukemia Group B Study 10301.

Analysis of Survival, AML Transformation, and Transfusion Independence in Patients with High-Risk Myelodysplastic Syndromes (MDS) Receiving Azacitidine Determined Using a Prognostic Model.

Azacitidine Prolongs Survival and Time to AML Transformation in High-Risk Myelodysplastic Syndrome (MDS) Patients ≥ 65 Years of Age.

Rates of Infection and Bleeding Are Not Increased in Patients with Myelodysplastic Syndromes (MDS) Treated with Azacitidine Compared with Supportive Care.

Response Rates Using International Working Group (IWG) Criteria in Patients with Myelodysplastic Syndromes (MDS) Treated with Azacitidine.

A New Validated Myelodysplastic Syndrome (MDS) Prognostic Model for Use When Cytogenetics Are Unavailable.

Response Rates in Patients with Acute Myeloid Leukemia (AML), Treated with Azacitidine, Using WHO and International Working Group (IWG) Criteria for Myelodysplastic Syndrome (MDS).

Email alerts

ASH Publications

American Society of Hematology

Bortezomib and Pegylated Liposomal Doxorubicin as Induction Therapy for Adult Patients with Symptomatic Multiple Myeloma: Cancer and Leukemia Group B Study 10301.

Analysis of Survival, AML Transformation, and Transfusion Independence in Patients with High-Risk Myelodysplastic Syndromes (MDS) Receiving Azacitidine Determined Using a Prognostic Model.

Azacitidine Prolongs Survival and Time to AML Transformation in High-Risk Myelodysplastic Syndrome (MDS) Patients ≥ 65 Years of Age.

Rates of Infection and Bleeding Are Not Increased in Patients with Myelodysplastic Syndromes (MDS) Treated with Azacitidine Compared with Supportive Care.

Response Rates Using International Working Group (IWG) Criteria in Patients with Myelodysplastic Syndromes (MDS) Treated with Azacitidine.

A New Validated Myelodysplastic Syndrome (MDS) Prognostic Model for Use When Cytogenetics Are Unavailable.

Response Rates in Patients with Acute Myeloid Leukemia (AML), Treated with Azacitidine, Using WHO and International Working Group (IWG) Criteria for Myelodysplastic Syndrome (MDS).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only